European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - oestrogens conjugated, bazedoxifene - postmenopause - conjugated estrogens and bazedoxifene - duavive is indicated for:treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.the experience treating women older than 65 years is limited.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 625microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - conjugated oestrogens - oral tablet - 625microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 1.25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - conjugated oestrogens - oral tablet - 1.25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - conjugated oestrogens - oral tablet - 625microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate; conjugated oestrogens - oral tablet - 10mg ; 625microgram

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.45 mg; bazedoxifene acetate, quantity: 22.56 mg (equivalent: bazedoxifene, qty 20 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; macrogol 400; magnesium stearate; sucrose palmitate; ascorbic acid; powdered cellulose; calcium phosphate; sucrose; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; iron oxide red; polydextrose; povidone; hyetellose; maltitol solution; poloxamer - duavive is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus.,- duavive should be used for the shortest duration consistent with treatment goals and risks for the individual woman.,- experience in women older than 65 years is limited.

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.625mg - conjugated estrogens 0.625mg - estrogens

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 1.25mg - conjugated estrogens 1.25mg - estrogens